novartis press release | News

Keyword	CPC	PCC	Volume	Score	Length of keyword
novartis press release	1.94	0.9	458	35	22
novartis	0.52	0.8	8567	38	8
press	0.03	0.7	7452	69	5
release	1.3	0.7	3990	64	7

Keyword	CPC	PCC	Volume	Score
novartis press release	0.78	0.8	2386	86
novartis press release iptacopan	1.51	0.7	7984	31
novartis ag press releases	0.03	1	5995	71
novartis asco press release	1.42	0.8	9935	86
novartis earnings press release	1.44	0.1	6743	82
novartis voyager press release	0.12	0.3	2224	79
novartis kisqali press release	0.51	0.9	5111	28
chinook novartis press release	1.77	0.8	5821	94

Search Results related to novartis press release on Search Engine

News | Novartis
novartis.com

https://www.novartis.com/news

WEBApr 17, 2007 · Apr 15, 2024. Media Release. New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN) Apr 11, 2024. Media Release. Novartis tender offer for MorphoSys AG commences. All news. Novartis 2023 Financial Results.

DA: 74 PA: 14 MOZ Rank: 81 Up or Down: Up

Novartis remibrutinib Phase III trials met their primary endpoints …
novartis.com

https://www.novartis.com/news/media-releases/novartis-remibrutinib-phase-iii-trials-met-their-primary-endpoints-and-showed-rapid-symptom-control-chronic-spontaneous-urticaria

WEBBasel, August 09, 2023 — Novartis today announced positive top-line results from the Phase III REMIX-1 and REMIX-2 studies evaluating remibrutinib 25 mg b.i.d., a Bruton’s tyrosine kinase (BTK) inhibitor, in patients with chronic spontaneous urticaria (CSU) whose symptoms are inadequately controlled by H1-antihistamines 1.

DA: 80 PA: 62 MOZ Rank: 30 Up or Down: Up

Novartis Pluvicto™ shows clinically meaningful and highly …
novartis.com

https://www.novartis.com/news/media-releases/novartis-pluvictotm-shows-clinically-meaningful-and-highly-statistically-significant-rpfs-benefit-patients-psma-positive-metastatic-castration-resistant-prostate-cancer-pre-taxane-setting

WEBOct 23, 2023. Phase III PSMAfore trial with Pluvicto™ met its primary endpoint of radiographic progression-free survival (rPFS) with a HR of 0.411; Pluvicto more than doubled median rPFS to 12.0 months per updated analysis*1.

DA: 76 PA: 26 MOZ Rank: 22 Up or Down: Up

Novartis announces new organizational structure to accelerate …
novartis.com

https://www.novartis.com/news/media-releases/novartis-announces-new-organizational-structure-accelerate-growth-strengthen-pipeline-and-increase-productivity

WEBBasel, April 4, 2022 — Novartis today announced the introduction of a new organizational structure and operating model designed to support the company’s innovation, growth, and productivity ambitions as a focused medicines company in the coming decade.

DA: 81 PA: 73 MOZ Rank: 54 Up or Down: Up

Novartis Kisqali® Phase III NATALEE trial meets primary …
novartis.com

https://www.novartis.com/news/media-releases/novartis-kisqali-phase-iii-natalee-trial-meets-primary-endpoint-interim-analysis-demonstrating-clinically-meaningful-benefit-broad-population-patients-early-breast-cancer

WEBBasel, March 27, 2023 — Novartis today announced positive topline results from an interim analysis of NATALEE, a Phase III trial evaluating Kisqali ® (ribociclib) plus endocrine therapy (ET) in a broad population of patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer (EBC) at ...

DA: 33 PA: 27 MOZ Rank: 23 Up or Down: Up

Novartis delivers double-digit sales growth and core margin …
novartis.com

https://www.novartis.com/news/media-releases/novartis-delivers-double-digit-sales-growth-and-core-margin-expansion-q1-fy-2024-guidance-raised

WEB1 day ago · “Novartis continued our strong momentum with both sales growth and core margin expansion in Q1. Our performance was broad-based, across all key growth brands and geographies, allowing us to raise guidance for the full year 2024. ... This press release contains forward-looking statements within the meaning of the United States Private ...

DA: 81 PA: 98 MOZ Rank: 16 Up or Down: Up

Novartis presents new long-term Leqvio® (inclisiran) data …
prnewswire.com

https://www.prnewswire.com/news-releases/novartis-presents-new-long-term-leqvio-inclisiran-data-demonstrating-consistent-efficacy-and-safety-beyond-six-years-301910740.html

WEBAug 28, 2023, 08:15 ET. Share this article. Results from the ORION-8 open-label extension trial show twice-yearly* Leqvio, in addition to statin therapy, provides consistent low-density lipoprotein...

DA: 98 PA: 35 MOZ Rank: 56 Up or Down: Up

FDA approves Novartis Leqvio® (inclisiran), first-in-class siRNA to
novartis.com

https://prod1.novartis.com/us-en/news/media-releases/fda-approves-novartis-leqvio-inclisiran-first-class-sirna-lower-cholesterol-and-keep-it-low-two-doses-year

WEBEAST HANOVER, December 22, 2021 -- Novartis today announced the US Food and Drug Administration (FDA) approval of Leqvio ® (inclisiran), the first and only small interfering RNA (siRNA) therapy to lower low-density lipoprotein cholesterol (also known as bad cholesterol or LDL-C) with two doses a year, after an initial dose and one at three months.

DA: 80 PA: 48 MOZ Rank: 53 Up or Down: Up

Novartis receives FDA approval for Fabhalta® (iptacopan), …
novartis.com

https://prod1.novartis.com/us-en/news/media-releases/novartis-receives-fda-approval-fabhalta-iptacopan-offering-superior-hemoglobin-improvement-absence-transfusions-first-oral-monotherapy-adults-pnh

WEBEAST HANOVER, N.J., Dec. 5, 2023 -- Novartis today announced that the U.S. Food and Drug Administration (FDA) approved Fabhalta ® (iptacopan) as the first oral monotherapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH) 1.

DA: 37 PA: 32 MOZ Rank: 72 Up or Down: Up

New Novartis data show early addition of twice-yearly* Leqvio
novartis.com

https://prod1.novartis.com/us-en/news/media-releases/new-novartis-data-show-early-addition-twice-yearly-leqvio-inclisiran-following-maximally-tolerated-statin-therapy-significantly-reduces-ldl-c-ascvd-patients-real-world-setting

WEBEAST HANOVER, N.J., April 6, 2024 Novartis today announced new data demonstrating the early addition of twice-yearly* Leqvio ® (inclisiran) to maximally tolerated statin therapy, prior to guideline-recommended ezetimibe, in a real-world setting significantly reduced low-density lipoprotein cholesterol (LDL-C) in patients with atherosclerotic car...

DA: 78 PA: 95 MOZ Rank: 6 Up or Down: Up